Add as a preferred source on Google

Baird Downgrades Insulet to Neutral and Cuts Price Target to $158

The firm lowered its target from $200 after a survey found weaker brand loyalty to automated insulin delivery systems than in the past.

An insulin pump rests beside an unbranded infusion set / TokenPost.ai
An insulin pump rests beside an unbranded infusion set / TokenPost.ai

Baird downgraded Insulet to Neutral from Overweight and cut its price target to $158 from $200 after a survey found weaker brand loyalty to automated insulin delivery systems than in the past.

The revised target represented about 19% upside from Friday’s close.

Loading…